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Abstract
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing fatal neurodegenerative disorder characterized by the selective
death of motor neurons (MN) in the spinal cord, and is associated with local neuroinflammation. Circulating CD4
+ T cells are
required for controlling the local detrimental inflammation in neurodegenerative diseases, and for supporting neuronal
survival, including that of MN. T-cell deficiency increases neuronal loss, while boosting T cell levels reduces it. Here, we show
that in the mutant superoxide dismutase 1 G93A (mSOD1) mouse model of ALS, the levels of natural killer T (NKT) cells
increased dramatically, and T-cell distribution was altered both in lymphoid organs and in the spinal cord relative to wild-
type mice. The most significant elevation of NKT cells was observed in the liver, concomitant with organ atrophy. Hepatic
expression levels of insulin-like growth factor (IGF)-1 decreased, while the expression of IGF binding protein (IGFBP)-1 was
augmented by more than 20-fold in mSOD1 mice relative to wild-type animals. Moreover, hepatic lymphocytes of pre-
symptomatic mSOD1 mice were found to secrete significantly higher levels of cytokines when stimulated with an NKT
ligand, ex-vivo. Immunomodulation of NKT cells using an analogue of a-galactosyl ceramide (a-GalCer), in a specific
regimen, diminished the number of these cells in the periphery, and induced recruitment of T cells into the affected spinal
cord, leading to a modest but significant prolongation of life span of mSOD1 mice. These results identify NKT cells as
potential players in ALS, and the liver as an additional site of major pathology in this disease, thereby emphasizing that ALS
is not only a non-cell autonomous, but a non-tissue autonomous disease, as well. Moreover, the results suggest potential
new therapeutic targets such as the liver for immunomodulatory intervention for modifying the disease, in addition to MN-
based neuroprotection and systemic treatments aimed at reducing oxidative stress.
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Introduction
Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig’s
disease is a rapidly progressing fatal neurodegenerative disorder,
with death occurring typically within 2–5 years after the
appearance of clinical symptoms. While the majority of ALS
cases are sporadic, 10 percent of them are inherited, with the most
abundant mutation occurring in the superoxide dismutase (SOD)-
1 gene [1]. In both its sporadic and genetic manifestations, disease
progression has been attributed to a selective death of motor
neurons (MN) in the spinal cord, with evidence for neuroin-
flammation and acquisition of a cytotoxic phenotype by resident
microglia [2,3,4].
Adaptive immunity is required to control the local detrimental
inflammation in neurodegenerative diseases, and is beneficial for
neuronal survival [5,6,7,8,9]. Specifically, it was shown that T cells
play a protective role in MN degeneration in the mutant
superoxide dismutase 1 G93A (mSOD1) mouse model of ALS
[10,11,12]. However, during the progression of this disease, a
systemic immune pathology involving thymic involution develops,
possibly reducing the naturally occurring neuroprotective immune
response [10,13].
Regulatory cells of the immune system include naturally
occurring and induced CD4
+CD25
+ Treg cells, myeloid suppressor
cells, CD8
+ regulatory cells, and natural killer T (NKT) cells
[14,15,16,17]. NKT cells share markers with both Natural Killer
(NK) and conventional T cells and are particularly abundant in the
liver [18,19]; the most well studied population is the invariant NKT
(iNKT) cell subset, which recognizes glycolipid antigens presented
by the non-classical major histocompatibility complex (MHC)-I-like
molecule, CD1d [20]. Upon activation by the prototypical antigen,
a-galactosylceramide(a-GalCer),oritsanalogue,PBS57,thesecells
rapidly release large amounts of cytokines [20,21].
NKT cells may be particularly active in neuroinflammation,
since the central nervous system (CNS) is enriched with glycolipids
[22]. Furthermore, as the number of NKT cells is reduced in
many autoimmune diseases, including multiple sclerosis, these cells
were suggested to act as suppressors of autoimmune reactions
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22374[15,23,24]. However, their role in other neurodegenerative
diseases with a local neuroinflammatory response remains unclear.
Here we found that NKT cells are elevated in the lymphoid
organs and CNS of mSOD1 mice. The most dramatic elevation
was observed in the liver, where NKT cells became the
predominant lymphocyte cell population, concomitantly with liver
atrophy, changes in IGF-1 axis, and pathological relocation of
lipids across the tissue. Administration of PBS57, a glycolipidic
ligand of NKT cells, in a specific regimen, delayed the onset of the
disease and prolonged the survival of mSOD1 mice. The
beneficial outcome of the treatment was correlated with down-
regulation of peripheral NKT cells and recruitment of T cells into
the affected spinal cord.
Materials and Methods
Animals
Wild-type (WT) and mSOD1
G93A mice on C57Bl or C57Bl/
SJL background were supplied by Harlan Biotech (Jerusalem,
Israel), the Animal Breeding Center of The Weizmann Institute of
Science, and the Jackson Laboratory.
Ethics statement
The animalsweretreatedandhandledaccordingtotheguidelines
of the Weizmann Institute’s Animal Care and Use Committee. The
study was approved by the Animal Care and Use Committee of the
Weizmann Institute, permit number: 03090608-1.
Administration of PBS57
A stock solution of PBS57 containing 2 mg/ml PBS57 in
dimethyl sulfoxide (DMSO) was dissolved in phosphate-buffered
saline (PBS) and injected i.p. (2 mg per mouse) in a final volume of
150 ml. Mice on a C57Bl/SJL background received a single
injection of PBS57 at day 60, and then four additional weekly
injections starting from the age of 95 days. Mice on a C57Bl
background received one injection at day 7062, and then two
weekly injections starting from the age of 10562 days.
PBS57 was kindly provided by Dr. Paul Savage (Department of
Chemistry and Biochemistry, Brigham Young University, Provo,
Utah).
Rota-rod
Prior to the development of symptoms, mice were trained to
stay on the Rota-rod (accelerating Rota-rod for mice 7650, Jones
and Roberts) with increasing velocity for 3 minutes. Starting from
95 days of age, their performance was assessed twice per week with
three daily sessions, by taking the best of the three sessions. Onset
age was defined as the age of the animal at the day when it failed
to complete the 3 minute run during all three sessions.
Flow cytometry
Mice at different stages of disease were perfused from the left
ventricle with PBS, and their spleens, livers, and spinal cords were
collected. The spleens were mashed, and the red blood cells were
lysed using ACK lysis buffer (Biosource, Rockville, MD.). Spinal
cords and livers were homogenized manually or using a software
controlled sealed homogenization system (Dispomix; http://www.
biocellisolation.com) followed by separation on a 40% Percoll (GE
Healthcare, Sweden) gradient to eliminate residual fat tissue. Liver
cell suspension was lysed with ACK lysis buffer following the
gradient separation. For florescence-activated cell sorting (FACS)
analysis, the following fluorochrome-labeled mAbs were used
according to the manufacturers’ protocols: FITC conjugated
anti-NK1.1, TCRb, Ly6C, LFA-1, and CD69; PE conjugated
anti-CD4, NK1.1, CD1d, and DX5; APC conjugated anti-TCRb,
CD11b, and FOXP3 (BD Pharmingen and eBioscience). APC-
conjugated a-GalCer-loaded CD1d tetramers (ProImmune) were
used according to the manufacturer’s protocol. Stained cells were
acquired using FACScan or Cyan flow cytometer and analyzed
using CellQuest (BD Biosciences), FlowJo (Tree Star), and Summit
(Dako cytometry) software.
Histology
After perfusion of the mice with PBS, the livers and spinal cords
were excised and fixed in 2.5% paraformaldehyde or Bouin, for
48 hours and then placed in 70% EtOH. The tissue was
dehydrated sequentially in EtOH:xylene:paraffin over a gradient
of 70:95:100% and then embedded in paraffin. Sections (6 mm
thick) were cut and stained using Nissl, periodic acid-Schiff (PAS)
reagent, hematoxylin and eosin.
Immunohistochemistry
Paraffin sections were prepared and stained, as described above.
The slides were then treated with 10 mM sodium citrate (pH 6.0)
by heating in the microwave to the boiling point, and then for a
further 10 min at 20% microwave power. Blocking was performed
with 20% normal horse serum with 0.05% saponin for 60 min.
Primary antibody mixture containing 2% normal horse serum and
0.05% saponin was applied for 24 h at 4uC in a humidified
chamber. For labeling of myeloid cells, FITC-conjugated Bandeir-
aea simplicifolia isolectin B4 (IB-4, 1:50; Sigma-Aldrich) and rat anti-
CD11b Abs (1:50, BD Pharmingen, Franklin Lakes, NJ) were
used. For labeling of astrocytes, rabbit anti-glial fibrillary acidic
protein (anti-GFAP) Abs were used (1:200; DAKO, Glostrup,
Denmark). Secondary antibodies included Cy-2-conjugated don-
key anti-mouse, Cy-3-conjugated donkey anti-mouse, Cy-3-
donkey anti-rat, and Cy-3-conjugated donkey anti rabbit (1:200;
Jackson ImmunoResearch, West Grove, PA). For nuclear staining,
Hoechst 33342 fluorochrome was used (Molecular Probes
Invitrogen). The stained sections were mounted with GVA
mounting solution (Invitrogen).
Quantitative real time polymerase chain reaction (Q-PCR)
Total cellular RNA purification and cDNA synthesis was
performed as described previously [5]. Q-PCR reactions were
performed with a high-speed thermal cycler (LightCycler; Roche
Diagnostics Corp.), and the product was detected by FastStart
MasterSYBR GreenI(Roche MolecularBiochemicals)accordingto
the manufacturer’s instructions. The amplification cycle was 95uC
for10seconds,60uC for 5 seconds, and 72uCfor10seconds.Melting
curve analysis confirmed that only a single product was amplified.
The following primers were used:
TNF-a forward 5.-ACAAGGCTGCCCCGACTAT-3.; reverse
5.-CTCCTGGTATGAAGTGGCAAATC-3.
IGF-1 forward 5.-CCGGACCAGAGACCCTTTG-3.; reverse
5.-CCTGTGGGCTTGTTGAAGTAAAA-3.
IGF-1R forward 5.-ATCCTGTGTTCTTCTATGTCC-3.;
reverse 5.-CCAACCTGCTGTTATTTCTC-3.
IGFBP-1 forward 5.-CCCAACAAAAGCAGGAG-3.; reverse
5.-TGTCTCACACTGTTTGCTG-3.
IGFBP-3 forward 5.-GAGACAGAATACGGTCCC-3.; reverse
5.-CCTTCTTGTCACAGTTTGG-3.
Measurement of cytokine production by hepatic
lymphocytes
Hepatic lymphocytes were prepared as described above, and
seeded (10
5 cells/well) in triplicates in 96 well plates in a final
NKT Cells and Liver Pathology in ALS
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serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 mM b-
mercaptoethanol, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin, and either supplemented with 100 ng/ml of PBS57 or left
untreated. The cells were incubated at 37uC/5% CO2 for 2 d.
Cytokine production was determined by enzyme-linked Immuno-
Sorbent assay (ELISA) of the cell medium, using a kit (eBioscience)
according to the manufacturer’s protocol.
Protein extraction
Spleen samples were weighed and then homogenized in cold
extraction buffer (Tris-buffered saline, pH 8.0, with 1% NP-40,
10% glycerol, 5 mM sodium metavanadate, 10 mM PMSF,
100 mg/ml aprotinin and 10 mg/ml leupeptin). Homogenates
were then centrifuged at 7000 g for 10 min, and supernatants
were assayed by ELISA.
Statistical analysis
Student’s t-test and analysis of variance (ANOVA) were
considered significant at p,0.05. Kaplan-Meier survival curves
were analyzed by Logrank test to generate an x
2 value for
significance. Statistical calculations were performed using standard
functions of Microsoft Excel, JMP, and Stat View software.
Results
Accumulation of NKT cells in the spinal cord, spleen and
liver of mSOD1 mice
The local inflammation in ALS, together with the compro-
mised protective immune response [10,13], encouraged us to
search for novel immunoregulatory targets in this disease. The
reported reduction of NKT cells in inflammatory autoimmune
diseases [23,25,26], on one hand, and the need for autoimmune
protective T cells in non-inflammatory neurodegenerative
diseases such as ALS [27], on the other hand, prompted us to
analyze the fate of these cells in ALS. We first examined whether
there is any homing of NKT cells to the affected spinal cord of
C57Bl/SJL mSOD1 mice, and found that their proportion
increased significantly at the clinical end-stage of the disease
(Fig. 1A). In the spleen, despite a reduction in its size, the
abundance of NKT was also found to be significantly in mSOD1
mice relative to WT (Fig. 1B), possibly resulting from
Figure 1. Accumulation of NKT cells in mSOD1 mice. FACS analyses (A–C) of the proportion of NKT, T, and NK cells in the spinal cord (n=4–7
per group), spleen, and liver (n=10–14 per group) in WT or mSOD1 mice on C57Bl/SJL background at the end-stage of the disease (day 135). (D) The
proportion of hepatic iNKT cells (n=4 per group), analyzed by expression of TCRb and binding of a-GalCer-loaded CD1d tetramers (CD1d/a-GC). (E)
Hepatic lymphocytes gated on T (R1) or NKT (R2) cells were analyzed for markers of activation state (CD49b) and migratory ability (Ly6c, LFA-1). Data
are expressed as mean6SEM; *p,0.05, **p,0.01, ***p,0.001 versus WT mice by Student’s t-test.
doi:10.1371/journal.pone.0022374.g001
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prominent increase in the proportion of NKT cells in the liver,
which also decreased in size as the disease progressed (see Fig. 2
and the section below) (Fig. 1C). In fact, the proportions of
NKT cells in the liver increased by 4-fold at the end-stage of the
disease. NKT-cell levels differ in mice of different genetic
backgrounds [28]. We therefore also measured the fate of NKT
cells in mSOD1 mice on a C57Bl background, and found similar
dynamics to the C57Bl/SJL background, with the hepatic NKT
cells becoming the predominant lymphocyte population with the
disease progression (Fig. S1).
Since spleen [10], thymus [13], and liver (Fig. 2A)a l ls h r i n ki n
size during disease progression, the change in lymphocyte
proportions in these organs does not necessarily reflect a change
in their absolute number. In order to investigate if the increase in
NKT cell population is accompanied by changes in the
abundance of other immune cells that share common markers
with NKT cells, we also determined the proportions of T cells
and NK cells in different organs of mSOD1 mice at the end-stage
of the disease. T cells were significantly elevated in the spinal
cord and spleen of mSOD1 mice relative to WT, although to a
lesser extent when compared to NKT cells (Fig. 1A–B). No
significant change in abundance of Treg cells was observed in the
spleen (data not shown). In contrast, the change in the proportion
of T cells in the liver did not mirror the corresponding change in
NKT cells, as T cell abundance was significantly lower in
mSOD1 liver relative to WT (Fig. 1C). NK cells were found to
be elevated significantly only in the spinal cord, but remained
unchanged in the spleen and the liver (Fig. 1A–C). Thus, the
changes in the proportion of NKT cells across different organs,
do not merely reflect alterations occurring in the populations of
T or NK cells.
To further characterize the population of NKT cells in the
periphery, we analyzed the phenotype of these cells in the
lymphoid organs of mSOD1 mice. The proportion of the CD1d-
reactive iNKT cell subpopulation was increased in the liver,
spleen, and thymus (Fig. 1D and Fig. S2). Furthermore, NKT
cells from mSOD1 mice expressed higher levels of the activation
marker, CD69, in the spleen and thymus (Fig. S2). Interestingly,
the migratory marker Ly6C and the integrin marker, CD49b,
associated with cell adhesion, were up-regulated on NKT but not
on conventional T cells in the liver, suggesting that hepatic NKT
cells acquire an activated state in mSOD1 mice (Fig. 1E). The
migratory protein, lymphocyte function associated antigen (LFA)-
1, remained constant on lymphocytes of mSOD1 mice relative to
WT, but a higher basal expression level was detected on NKT cells
compared to conventional T cells (Fig. 1E). Collectively, these
results identify specific changes in lymphocyte populations in the
liver of mSOD1 mice, and suggest that accumulation of NKT cells
in the CNS might stem from their selective recruitment from the
periphery.
Liver pathology, inflammation, and changes in IGF-1 axis
in mSOD1 mice
Since the most notable elevation in NKT cells was observed in
the liver, we searched for pathological changes in this organ, and
found that its absolute weight, as well as its proportion relative to
body mass, was significantly reduced in mSOD1 mice (Fig. 2A).
The liver weight reduction was accompanied by hepatocyte
atrophy (Fig. 2B,C), and weak staining with periodic acid-Schiff
reagent (PAS), possibly indicating a depletion of glycogen storage
(Fig. 2C). Staining with Oil Red revealed lipid aggregation
during the course of disease progression (Fig. 2D), partially co-
localized with, or surrounded by isolectin (IB)-4 binding cells
(Fig. 2E). A marked elevation in IB-4 stained cells was evident in
the diseased animals (Fig. 2E). In order to further characterize
the identity of the IB-4
+ cells found in the liver, we stained them
with the myeloid marker CD11b and found that these markers
were colocalized (Fig. 2F). Since CD1d is involved in glycolipid
presentation to NKT cells [18,20], we looked for expression
levels of CD1d on CD11b
+cells; no further elevation relative to
WT was found in the diseased animals (data not shown). It is
therefore possible that the pathological conditions that develop in
the liver may be associated with an increase in the proportion of
antigen presenting cells for the NKT population. In addition, we
found in the liver a high expression levels of tumor necrosis factor
(TNF)-a (Fig. 2G), indicating that the disease manifestation was
correlated with a hepatic inflammatory response. Since the liver
is the main source of IGF-1, a key MN survival protein in ALS
[29], we measured its expression in the liver and found a
significant reduction in mSOD1 mice (Fig. 2H). We also
observed a slight increase in IGF-1 receptor (IGF-1R) in the liver
that was not statistically significant (Fig. 2I). IGF-1 availability
and its biological effects are strongly regulated by IGF-1 binding
proteins (IGFBPs), which are presumably synthesized and
released into the circulation by the liver [30]. Measurement of
IGFBP-1 revealed a dramatic increase (by more than 20 fold) in
its expression levels in the liver of mSOD1 mice relative to WT
(Fig. 2J). Testing IGFBP-3 revealed a slight increase that was not
statistically significant (Fig. 2K). Taken together, these results
suggest that the disease progression in mSOD1 mice is correlated
with liver inflammation, atrophy, and a decrease in the
production and possible availability of IGF-1.
NKT cell-based immunomodulation delays the onset of
clinical symptoms and prolongs the survival of mSOD1
mice
Since we found that NKT cell abundance increased in
mSOD1 mice, we envisioned that these cells might be involved
in disease progression. One possible mechanism for such an
involvement could be via suppression of peripheral immunity
needed for fighting off the disease [31]; thus, their manipulation
might provide an effective therapeutic approach. We therefore
focused on the immunomodulatory ligand, a-GalCer [20],
which was shown to induce anergy and hypo-responsiveness of
NKT cells following repeated administration [32]. To test the
effect of manipulation of NKT cells on disease progression, we
subjected mSOD1 mice to treatment with a soluble a-GalCer
analog, PBS57 [21]. The animals received a single injection of
PBS57 at day 60, and then four additional weekly injections
starting from the age of 95 days (according to the regimen
described in Fig. 3A). A significant prolongation of lifespan (by
7 days) was observed in the treated animals (Fig. 3A)a n dt h e
first appearance of clinical symptoms was also significantly
delayed in the PBS57 treated group, by 7 days (Fig. 3B),
suggesting that manipulating NKT cells attenuated the disease
progression at the preclinical stage. The outcome of the
treatment was very sensitive to the regimen; no effect on
survival or on clinical symptoms (with a non-significant trend for
an adverse effect) was observed in animals that received PBS57
weekly starting from day 60 (data not shown). Therefore, in all
subsequent experiments we used only the protocol of a first
injection on day 60, and weekly injection from day 95 onward.
These results suggest that the treatment with PBS57 increases
the life span of the animals by delaying the onset of the clinical
symptoms of the disease, rather than prolonging the progression
phase.
NKT Cells and Liver Pathology in ALS
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mass of WT and mSOD1 mice on C57Bl/SJL background, and representative pictures of the tissue. (B) Quantitative analysis of hepatocyte diameter
using Hematoxylin & Eosin (H&E) stained liver. (C) Representative micrographs of H&E and PAS stained livers depicting changes in hepatocyte size
and reduction in PAS-positive material. Scale bars represent 50 mm and 100 mm, respectively. Note the loss of granular composition in the cytoplasm
along the course of disease progression. (D) Liver staining with Oil Red demonstrating marked lipid redistribution in the disease. Scale bar is 25 mm.
Specifically, lipid droplets accumulated in extracellular spaces, or were partially co-localized (E) with IB-4 positive cells (quantified at different stages
of the disease; arrows indicate double-labeled cells). Scale bar represents 25 mm. (F) Representative micrograph of liver sections stained for IB-4
(green), CD11b (red), and Hoechst staining for nuclear content (blue). Scale bar represents 50 mm. The majority (up to 80%) of IB-4
+ cells also
expressed CD11b; arrows indicate double-labeled cells (split images include high magnification fields of the white boxed area). (G–K) Expression of
TNF-a, IGF-1, IGF-1R, IGFBP1, and IGFBP3 from liver samples of WT and mSOD1 mice at day 135, as determined by Q-PCR. Data are expressed as
mean6SEM (n=3–6 per group). *p,0.05, **p,0.01, ***p,0.001 versus WT mice by one-way ANOVA followed by Student’s t-test post-hoc analysis.
doi:10.1371/journal.pone.0022374.g002
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astrogliosis in the spinal cord
We next wished to determine whether immunomodulation of
NKT cells could affect the MN pathology observed in the spinal
cord. To that end, we counted and compared the number of MNs
in lumbar spinal cord sections of untreated mSOD1 mice at age
130–135 days (the average age of death of this group) with that of
age-matched PBS7 treated mSOD1 mice. A marked reduction in
the number of MNs was observed in mSOD1 untreated mice,
while treatment with PBS57 resulted in a significant attenuation of
MN loss (Fig. 4A). Since glial pathology is one of the hallmarks of
ALS [33,34,35], we tested whether administration of PBS57
affected astrocyte activation, by staining for glial fibrillary acidic
protein (GFAP). GFAP expression was abundant throughout the
lumbar part of the spinal cord in mSOD1 mice, while in PBS57-
treated animals it was significantly reduced (Fig. 4B). In fact, in
PBS57-treated animals, GFAP expression was restricted only to
the caudal sections, indicating that disease progression in the
caudal-rostral direction is attenuated by the treatment.
Modulation of NKT cells induces a cytokine shift in the
liver, and recruits T cells into the spinal cord
To gain insight into the immunological effect of PBS57, the
fate of NKT cells following the treatment was assessed. In
PBS57-treated mSOD1 mice we found a significant reduction in
the proportion of NKT cells in the spleen, thymus, and liver
compared to untreated mSOD1 mice at the end-stage of the
disease (Fig. 5A and Fig. S3A) .T h e s er e s u l t sa r ei nl i n ew i t h
reports that repeated administration of a-GalCer depletes the
number of NKT cells and down-regulates their activation state
[32,36]. In addition, we found that the hepatic T-cell population
was restored to the levels observed in the WT animals (Fig. 5A).
PBS57 administration also resulted in a significant reduction in
CD69 expression on NKT cells (Fig. 5A and Fig. S3A),
suggesting that the decrease in NKT cells was accompanied by
modulation of their activation state, as well. Notably, treatment
with PBS57 resulted in attenuation of liver atrophy (Fig. 5B),
without affecting the expression levels of IGF-1 (data not shown).
Since we observed that PBS57 treatment delayed the onset of
clinical symptoms and reversed the accumulation of NKT cells in
the late stage of the disease, we further investigated whether any
pathological changes could be observed in hepatic lymphocytes
before the first appearance of clinical symptoms (around day 105).
We did not find any changes in the proportions of NKT cells or T
cells in the liver of pre-symptomatic mSOD1 mice relative to WT
(data not shown). The above results prompted us to explore
whether there were any early pathological changes in the cytokine
profile of hepatic lymphocytes in mSOD1 mice, and whether these
Figure 3. Administration of PBS57 extends survival of mSOD1 mice. (A) Repeated administration of PBS57 to mSOD1 female mice on C57Bl/
SJL background according to the described regimen resulted in increased survival, as shown by average survival time and corresponding Kaplan-
Meier curves for untreated (n=21) versus PBS57 treated (n=18) mice (Logrank x
2=8.9, p,0.005). (B) Rota-rod performance of control (n=21) and
PBS57-treated (n=18) mice (repeated measures ANOVA of the effect of the treatment on Rota-rod performance. Groups: p=0.069; days: p=0.0001;
groups*days: p=0.0092). Onset age was defined as the age of the animal at the day it failed to complete a 3 minute run on at least one of three
sessions on the Rota-rod. Inset displays the average onset age (Logrank x
2=6.69, p,0.01). Note a significant delay in clinical disease onset in treated
mice. Data are expressed as mean 6 SEM. * p,0.05, ** p,0.01 by Student’s t-test analysis.
doi:10.1371/journal.pone.0022374.g003
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To that end, hepatic lymphocytes were harvested from WT,
mSOD1 control, and mSOD1 PBS57-treated mice, and were
tested for cytokine secretion in-vitro with and without further ex-vivo
treatment with PBS57. Importantly, we found that ex-vivo activated
lymphocytes, harvested from untreated mSOD1 mice, secreted
higher levels of all tested cytokines (interleukin (IL)-10, IL-4, TNF-
a, and interferon (IFN)-c) relative to cells harvested from WT
mice, with the most pronounced increase in TNF-a (Fig. 5C). In
contrast, hepatic lymphocytes that were harvested from mSOD1
mice 3-days after the third injection of PBS57 (when the mice were
105 days old), and cultured ex-vivo with PBS57 showed a marked
reduction in the capacity to secrete these cytokines, with some
retention of IL-10 secretion (Fig. 5C). Despite the suppression of
the capacity of NKT cells to induce cytokine release upon
stimulation, the treatment did not result in an overall state of
immunosuppression; when we quantified the actual cytokine levels
in tissue-extracts, we found a marked increase in the levels of IFN-
c in the total spleen extracts of PBS57-treated mice (Fig. S3B).
We further investigated whether the immunomodulation of
NKT cells with PBS57 could affect the recruitment of T cells into
the diseased spinal cord before the onset of the disease. We
therefore repeated the treatment regimen and found that 3 days
after the third injection of PBS57, treated mSOD1 mice had
significantly elevated proportions of T cells in the spinal cord,
compared to their untreated mSOD1 littermates (Fig. 6A). There
was also a slight increase in the proportion of NKT cells in the
affected spinal cord following treatment, which was not statistically
significant (Fig. 6B). Importantly, treatment with PBS57 did not
affect the proportions of T cells in the spinal cord of WT animals,
indicating that the mSOD1-associated pathology is a prerequisite
for the recruitment of T cells into the spinal cord.
Collectively, these results suggest that there is a pathological
activation of liver NKT cells in mSOD1 mice, which develops
before the appearance of clinical symptoms of the disease, and
precedes the accumulation of NKT cells in the spinal cord and
lymphoid organs. In addition, modulation of NKT cells by PBS57
reverses the phenotype of NKT cells in the liver and results in an
increased recruitment of T cells into the spinal cord, leading to a
delay in the clinical onset of the disease.
Discussion
In this study, we observed a robust increase in NKT cells in
lymphoid organs and the spinal cord of mSOD1 mice along the
pathway of disease progression. In addition, liver parenchyma
underwent significant atrophy and lipid redistribution, together
with marked changes in IGF-1 and its binding proteins. We
further demonstrated that as a result of down-regulation of NKT-
cell activity by PBS57, administered in a specific regimen, T cells
were recruited into the spinal cord, disease onset was delayed, and
lifespan was increased. Importantly, we tested only two PBS57
protocols, out of which only one showed a beneficial effect, though
modest. Yet, these results suggest that further studies optimizing
dose and timing may lead to a more effective treatment regimen.
For more than two decades, there has been evidence suggesting
altered lipid metabolism and pathologic accumulation of gangli-
osides in the muscles and CNS of ALS patients [37,38,39]. In
mSOD1 mice, increased lipolysis and depletion of adipose stores
was reported, with a high-fat diet shown to prolong survival [40].
As such, hyperlipidemia was suggested as a positive prognostic
factor predicting prolonged survival of ALS patients [41].
Accordingly, our finding that NKT cells are elevated in mSOD1
mice might stem from their activation by putative endogenous
ligands in the periphery as a result of altered lipid metabolism.
Alternatively, the increased proportion of NKT cells might result
from lymphopenic conditions that progressively develop in ALS
[10]. Moreover, the accumulation of NKT cells in the mSOD1
spinal cord might not necessarily depend on antigen specificity, as
it was shown that the recruitment of NKT cells to CNS lesions in
Figure 4. Administration of PBS57 delays MN death in mSOD1 mice. (A) Representative micrographs of spinal cord sections at end-stage
disease, and quantitative analysis of the number of MNs detected by Nissl staining in WT mice and mSOD1, relative to PBS57-treated littermates. Scale
bars are 100 mm. (B) Representative micrographs and quantitative analysis of GFAP-reactive astrocytes in the affected spinal cord. Glial activation and
tissue disorganization were reduced by PBS57 treatment (insets are high magnification enlargements of white-boxed areas with Hoechst staining for
nuclear content in blue). Scale bars in B correspond to 100 mm, insets to 25 mm. Data are expressed as mean6SEM (n=3-6 per group). *p,0.05,
**p,0.01, ***p,0.001 versus WT mice by Student’s t-test, or one-way ANOVA followed by Student’s t-test post-hoc analysis.
doi:10.1371/journal.pone.0022374.g004
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CNS antigen presentation [42].
In addition to the marked neuroinflammatory component in the
spinal cord in ALS, accumulating evidence suggests pathology of
the peripheral immune system, as well [10,13,43,44]. CD4
+ T cells
were shown to play a role in protecting neurons in general [8,45],
and MN in mSOD1 mice in particular [10], while immune
deficiency in these mice resulted in reduced life expectancy
[11,12]. These findings are consistent with the concept of
‘‘protective autoimmunity’’, developed by our group, stating that
adaptive immunity is required to help control the detrimental local
inflammatory response (involving mainly the resident microglia
and possibly the scar forming astrocytes), which develops under
acute or chronic neurodegenerative conditions in the CNS
[5,6,7,8,46,47]. Boosting of the protective autoimmune response
with the random copolymer, glatiramer acetate, which weakly
cross-reacts with self-antigens [48], was shown to have protective
effect in animal models of chronic neurodegenerative diseases such
as glaucoma and Alzheimer’s disease when given infrequently
(weekly or monthly but not daily) [5,49,50]. In the case of ALS,
immunization with glatiramer acetate was shown to be beneficial
only when emulsified in adjuvant in the low mSOD1 copy number
model of ALS [51]. However, administration of glatiramer acetate
has limited effects [10,52], or even leads to adverse effects [53],
when given without adjuvant or when administered repeatedly in
the high mSOD1 copy number model of ALS, possibly as a result
of immune suppression induced by this regimen [54].
Our present findings of elevated NKT cell levels in lymphoid
organs of mSOD1 mice and an increase in the capacity of hepatic
lymphocytes to secrete cytokines in response to NKT-cell
stimulation, might indicate an additional aspect of the aberrant
regulation of the immune response in ALS. Manipulating these
cells by administration of PBS57 in the regimen used here resulted
in a reduction in the number of NKT cells and their
hyporesponsiveness, and concomitantly delayed appearance of
clinical symptoms and prolonged survival. The approach under-
taken in this study was aimed to demonstrate that NKT cells play
an immunomodulatory role in a complex neurodegenerative
disease such as ALS, therefore representing a novel therapeutic
target for intervention. The apparent insufficiency of NKT cells in
autoimmune diseases that are associated with an overwhelming
adaptive immune response [15,23,25,26], and their high numbers
in ALS, a disease that is associated with compromised adaptive
immunity [10,13], suggest that this population of cells might
be one of the non cell-autonomous factors in ALS
[1,2,3,33,34,35,55]. To determine whether accumulation of these
cells is a co-morbidity factor that causally contributes to disease
progression, future studies involving the direct depletion of NKT
cells must be conducted. Moreover, to establish whether NKT cell
pathology is a general hallmark of ALS, these cells should be
characterized in ALS patients, as well as in additional animal
models of the disease, including a model of low copy number of
mSOD1, and mice that overexpress the human WT SOD1
protein.
IGF-1 is a key neuronal survival protein, in general, and in ALS,
in particular [29]. It is produced locally in the CNS by neurons
and glia, but its main source in the circulation is the liver [56].
After liver injury, IGF-1 was shown to facilitate hepatocyte
regeneration, and liver-specific IGF-1R knockout results in
inhibition of this process [57]. The function of IGF-1 is tightly
Figure 5. Immunomodulation with PBS57 downregulates NKT cells and increases T cells in the liver. (A) NKT, iNKT, and T cells were
monitored at the end-stage of the disease in the liver of PBS57-treated or untreated mSOD1 mice on C57Bl/SJL background. The proportion of each
cell population and the activation state of NKT cells (defined by CD69 expression) are shown normalized to values obtained for WT controls. (B)
Diameter of hepatocytes was measured in untreated mSOD1 at the end-stage of the disease and in age-matched PBS57 treated mSOD1 mice, and
normalized to levels observed in WT animals. (C) Hepatic lymphocytes, harvested from WT or mSOD1 mice 3 days after the 3rd injection of PBS57
(day 105), were tested for cytokine production following ex-vivo stimulation. In-vivo treatment with PBS57 resulted in abrogation of cytokine
production following subsequent ex-vivo stimulation, with some retention of IL-10 secretion. Data are expressed as mean6SEM (n=3–6 per group).
*p,0.05, **p,0.01, ***p,0.001 versus WT mice or unstimulated lymphocytes by Student’s t-test, or one-way ANOVA followed by Student’s t-test
post-hoc analysis.
doi:10.1371/journal.pone.0022374.g005
Figure 6. Immunomodulation with PBS57 recruits T cells into the spinal cord of mSOD1 mice. Lymphocytes were harvested from the
spinal cord of WT and mSOD1 mice on a C57Bl background 3 days after the 3rd injection of PBS57 (day 115), and were tested for the proportion of T
cells (A), and NKT cells (B) by FACS. A robust increase in the proportion of T cells was observed in the spinal cord of mSOD1 mice that were treated
with PBS57. Notably, the treatment did not affect the proportions of lymphocytes in the spinal cord of healthy WT animals. Data are expressed as
mean6SEM (n=3-6 per group). **p,0.01, ***p,0.001 versus WT mice by one-way ANOVA followed by Student’s t-test post-hoc analysis.
doi:10.1371/journal.pone.0022374.g006
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life in circulation (mainly IGFBP-3), but also inhibit its
bioavailability [58]. Accumulating evidence suggest that IGFBPs
have also intrinsic activities that are IGF-independent [59]. For
instance, IGFBP-1 was shown to increase rapidly after partial
hepatectomy, and was suggested to be a critical hepatic survival
factor by reducing the levels of pro-apoptotic signals [60]. Thus
the robust elevation of IGFBP-1 and the changes in IGF-1 axis
observed in mSOD1 mice might reflect a local physiological
attempt of hepatocyte regeneration in response to continuous liver
damage. However, even if the increase in IGFBPs retards liver
degeneration, it could limit the availability of circulating IGF-1 to
MN. Interestingly, it was suggested that circulating IGF-1 can
enter the CNS by means of low density lipoprotein receptor-
related protein, megalin [61]. Our preliminary results indicate that
mSOD1 mice had lower expression levels of megalin in the spinal
cord during disease progression, as compared to WT controls (not
shown). Importantly, at this stage we cannot determine if liver and
IGF-1 related pathology contributes causally to the development
of ALS symptoms, or if it is merely an epi-phenomenon reflecting
systemic aberrations resulting from the ubiquitous expression of
mSOD1 protein in this mouse model. Nevertheless, as there is also
evidence for changes in the liver of patients with sporadic forms of
MN disease (including ALS) [41,62], these findings call for
development of new therapies that will directly target the liver
pathology, in addition to MN-based neuroprotection and systemic
treatments aimed at reducing oxidative stress [63].
In addition to growth factors such as IGF-1, cytokines likeTNF-a
were also found to support liver regeneration [64]. However TNF-a
secreted by activated NKT cells was shown to exacerbate liver
injury [65]. Therefore, the overall increase in hepatic NKT cells
might eventually result in liver inflammation and hepatocyte
damage. Accordingly, we found that treatment with PBS57
attenuated liver atrophy and reduced the capacity of hepatic
lymphocytes to secrete TNF-a, though it failed to reverse the
reductionin hepaticIGF-1. This failuremight reflect the apparently
irreversible severe pathological changes in the liver, possibly due to
mitochondrial damage similar to that occurring in MN
[62,66,67,68,69]. Importantly, irreversible liver atrophy might
explain the limited effect of the current treatment in mSOD1 mice
as well as the limited success of many other potential ALS
treatments tested. Nevertheless, it is still possible that elevation of
NKT cells in the liver is part of a general attempt of the tissue to
facilitate hepatocyte regeneration by means of TNF-a secretion.
Regardless of the reason as to why NKT cell levels and
activation state increase in mSOD1 mice, their presence seemed to
contribute to the failure to mount a protective T-cell response in
the disease. NKT cells were shown to control effector T cells
through various mechanisms including inhibition of IL-2 produc-
tion, changing the properties of antigen presenting cells, and
potentiation of Treg and myeloid suppressor cells
[17,24,25,70,71,72]. Administration of a-GalCer in the regimen
used in the present study might result in an altered cytokine
repertoire, together with anergy and even apoptosis of NKT cells,
with possible lifting of T cell suppression [32,36]. Interestingly, a
high-fat diet, which was beneficial in ALS [40], was shown to
induce apoptosis of NKT cells in the liver, via release of
proinflammatory cytokines by immature myeloid cells [73]. Since
repeated administration of glycolipid ligands may lead to NKT cell
anergy and hyporesponsivness [32], it is possible that the
therapeutic approach taken here converges into a common
pathway of evoking a more efficient response of CD4
+ T cells
together with blocking the inflammatory response in the liver. In
fact, we found that modulation of NKT cells by PBS57 induced
recruitment of T cells into the spinal cord before the onset of
clinical symptoms. In turn, such a T-cell response may lead to
local production of IGF-1 in the spinal cord, by regulating
microglial activity and recruitment of blood-born monocytes,
collectively resulting in immunomodulation of the CNS milieu,
and thereby favoring neuronal survival [5,11,12,74,75].
In conclusion, our understanding of the neuroinflammatory
component in ALS is extended by the current observations that
NKT cells are altered in the mSOD1 disease model. Evidence of
liver inflammation and changes in IGF-1 axis together with the
finding that modulating the activity of NKT cells is beneficial in
mSOD1 mice, provide further support for the necessity of a proper
immune response in ALS, and suggests novel secondary targets for
therapeutic intervention in this disease and for other related
neurodegenerative conditions.
Supporting Information
Figure S1 Peripheral changes in lymphoid populations
in mSOD1 mice on C57Bl background. FACS analysis of
NKT and T cells from WT and mSOD1 mice at the progression
(day 130) and end-stage (day 150) of the disease. The most
prominent change was the increase in the proportion of NKT cells
in all tissues tested, particularly in the liver. Data are expressed as
mean6SEM (n=7-12 for WT, n=4-8 for mSOD1 at day 130,
and n=4-7 for mSOD1 mice at day 150).
(TIF)
Figure S2 Alteration in lymphocyte distribution in the
thymus and spleen of mSOD1 mice. The proportion of
hepatic iNKT cells was analyzed by FACS analysis of TCRb
expression, and binding of a-GalCer-loaded CD1d tetramers
(CD1d/a-GC). Markers of activation (CD69), and migration
(Ly6c) on gated T (R1) and NKT (R2) cells in the spleen and
thymus of WT or mSOD1 mice at disease end-stage were tested
by FACS. Both T and NKT cells from mSOD1 mice expressed
higher levels of Ly6C as compared to WT, whereas CD69 was up-
regulated only on NKT cells. Data are expressed as mean6SEM
(n=3-6 per group).
(TIF)
Figure S3 PBS57 attenuates NKT cells elevation in the
spleen and thymus of mSOD1 mice and boosts IFN-c
levels. (A) The effect of PBS57 treatment was examined by
monitoring the proportion of NKT, iNKT, and the activation
state of NKT cells (defined by CD69 expression) in WT or
mSOD1 mice at the end-stage of the disease by FACS. Values
shown are normalized to those of WT controls. (B) IFN-c levels in
the spleen of WT or mSOD1 mice were determined by ELISA 3
days after the 3rd injection of PBS57. Data are expressed as
mean6SEM (n=3-6 per group). *p,0.05, **p,0.01 by Student’s
t-test, or one-way ANOVA followed by Student’s t-test post-hoc
analysis.
(TIF)
Acknowledgments
We would like to thank Dr. Paul Savage and his group for kindly providing
us with PBS57 and Mrs. Margalit Azoulay for animal maintenance. M.S.
holds the Maurice and Ilse Katz Professorial Chair in Neuroimmunology.
Author Contributions
Conceived and designed the experiments: AF GK MS. Performed the
experiments: AF GK AS AR TB DA. Analyzed the data: AF GK.
Contributed reagents/materials/analysis tools: MKH. Wrote the paper:
AF GK MS.
NKT Cells and Liver Pathology in ALS
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e22374References
1. Rosen DR, Siddique T, Patterson D, lewicz DA, Sapp P, et al. (1993) Mutations
in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic
lateral sclerosis. Nature 362: 59–62.
2. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, et al. (2006)
Onset and progression in inherited ALS determined by motor neurons and
microglia. Science 312: 1389–1392.
3. Xiao Q, Zhao W, Beers DR, Yen AA, Xie W, et al. (2007) Mutant SOD1(G93A)
microglia are more neurotoxic relative to wild-type microglia. J Neurochem 102:
2008–2019.
4. Gowing G, Philips T, Van Wijmeersch B, Audet JN, Dewil M, et al. (2008)
Ablation of proliferating microglia does not affect motor neuron degeneration in
amyotrophic lateral sclerosis caused by mutant superoxide dismutase. J Neurosci
28: 10234–10244.
5. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, et al. (2006)
Glatiramer acetate hts against Alzheimer’s disease by inducing dendritic-like
microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A 103:
11784–11789.
6. Hauben E, Agranov E, Gothilf A, Nevo U, Cohen A, et al. (2001) Posttraumatic
therapeutic vaccination with modified myelin self-antigen prevents complete
paralysis while avoiding autoimmune disease. J Clin Invest 108: 591–599.
7. Kipnis J, Mizrahi T, Hauben E, Shaked I, Shevach E, et al. (2002)
Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory
T cells suppress the ability to withstand injury to the central nervous system.
Proc Natl Acad Sci U S A 99: 15620–15625.
8. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, et al. (1999)
Autoimmune T cells protect neurons from secondary degeneration after central
nervous system axotomy. Nat Med 5: 49–55.
9. Frenkel D, Huang Z, Maron R, Koldzic DN, Moskowitz MA, et al. (2005)
Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic
stroke. J Neurol Sci 233: 125–132.
10. Banerjee R, Mosley RL, Reynolds AD, Dhar A, Jackson-Lewis V, et al. (2008)
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis
mice. PLoS ONE 3: e2740.
11. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH (2008) CD4+ T cells support
glial neuroprotection, slow disease progression, and modify glial morphology in
an animal model of inherited ALS. Proc Natl Acad Sci U S A 105:
15558–15563.
12. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, et al. (2008) T
lymphocytes potentiate endogenous neuroprotective inflammation in a mouse
model of ALS. Proc Natl Acad Sci U S A 105: 17913–17918.
13. Seksenyan A, Ron-Harel N, Azoulay D, Cahalon L, Cardon M, et al. Thymic
involution, a co-morbidity factor in amyotrophic lateral sclerosis. J Cell Mol
Med 4: 2470–2482.
14. Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, et al. (2008)
Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett
267: 216–225.
15. Hammond KJ, Kronenberg M (2003) Natural killer T cells: natural or unnatural
regulators of autoimmunity? Curr Opin Immunol 15: 683–689.
16. Pomie C, Menager-Marcq I, van Meerwijk JP (2008) Murine CD8+ regulatory
T lymphocytes: the new era. Hum Immunol 69: 708–714.
17. La Cava A, Van Kaer L, Fu Dong S (2006) CD4+CD25+ Tregs and NKT cells:
regulators regulating regulators. Trends Immunol 27: 322–327.
18. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, et al. (1995) CD1
recognition by mouse NK1+ T lymphocytes. Science 268: 863–865.
19. Kawamura T, Takeda K, Kaneda H, Matsumoto H, Hayakawa Y, et al. (2009)
NKG2A inhibits invariant NKT cell activation in hepatic injury. J Immunol
182: 250–258.
20. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. (1997) CD1d-restricted
and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.
Science 278: 1626–1629.
21. Liu Y, Goff RD, Zhou D, Mattner J, Sullivan BA, et al. (2006) A modified alpha-
galactosyl ceramide for staining and stimulating natural killer T cells. J Immunol
Methods 312: 34–39.
22. Halder RC, Jahng A, Maricic I, Kumar V (2007) Mini review: immune response
to myelin-derived sulfatide and CNS-demyelination. Neurochem Res 32:
257–262.
23. van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, et al.
(2001) Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a
wide variety of diseases that are characterized by autoreactive tissue damage.
Clin Immunol 100: 144–148.
24. Grajewski RS, Hansen AM, Agarwal RK, Kronenberg M, Sidobre S, et al.
(2008) Activation of invariant NKT cells ameliorates experimental ocular
autoimmunity by a mechanism involving innate IFN-gamma production and
dampening of the adaptive Th1 and Th17 responses. J Immunol 181:
4791–4797.
25. Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A (2002) NKT cells inhibit the
onset of diabetes by impairing the development of pathogenic T cells specific for
pancreatic beta cells. Immunity 17: 725–736.
26. Mars LT, Laloux V, Goude K, Desbois S, Saoudi A, et al. (2002) Cutting edge:
V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune
encephalomyelitis in nonobese diabetic mice. J Immunol 168: 6007–6011.
27. Schwartz M, Ziv Y (2008) Immunity to self and self-maintenance: what can
tumor immunology teach us about ALS and Alzheimer’s disease? Trends
Pharmacol Sci 29: 287–293.
28. Serizawa I, Koezuka Y, Amao H, Saito TR, Takahashi KW (2000) Functional
natural killer T cells in experimental mouse strains, including NK1.1- strains.
Exp Anim 49: 171–180.
29. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH (2003) Retrograde viral
delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301:
839–842.
30. Zimmermann EM, Li L, Hoyt EC, Pucilowska JB, Lichtman S, et al. (2000)
Cell-specific localization of insulin-like growth factor binding protein mRNAs in
rat liver. Am J Physiol Gastrointest Liver Physiol 278: G447–457.
31. Schwartz M, Shechter R Systemic inflammatory cells ht off neurodegenerative
disease. Nat Rev Neurol.
32. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, et al. (2005)
Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin
Invest 115: 2572–2583.
33. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, et al. (2008)
Astrocytes as determinants of disease progression in inherited amyotrophic
lateral sclerosis. Nat Neurosci 11: 251–253.
34. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, et al. (2006) Wild-type
microglia extend survival in PU.1 knockout mice with familial amyotrophic
lateral sclerosis. Proc Natl Acad Sci U S A 103: 16021–16026.
35. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, et al. (2007) Astrocytes
expressing ALS-linked mutated SOD1 release factors selectively toxic to motor
neurons. Nat Neurosci 10: 615–622.
36. Uldrich AP, Crowe NY, Kyparissoudis K, Pellicci DG, Zhan Y, et al. (2005)
NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent
expansion, Bim-dependent contraction, and hyporesponsiveness to further
antigenic challenge. J Immunol 175: 3092–3101.
37. Dawson G, Stefansson K (1984) Gangliosides of human spinal cord: aberrant
composition of cords from patients with amyotrophic lateral sclerosis. J Neurosci
Res 12: 213–220.
38. Kundu SK, Harati Y, Misra LK (1984) Sialosylglobotetraosylceramide: a
marker for amyotropic lateral sclerosis. Biochem Biophys Res Commun 118:
82–89.
39. Rapport MM, Donnenfeld H, Brunner W, Hungund B, Bartfeld H (1985)
Ganglioside patterns in amyotrophic lateral sclerosis brain regions. Ann Neurol
18: 60–67.
40. Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loeffler JP (2004)
Evidence for defective energy homeostasis in amyotrophic lateral sclerosis:
benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad
Sci U S A 101: 11159–11164.
41. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D,
et al. (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.
Neurology 70: 1004–1009.
42. Mars LT, Gautron AS, Novak J, Beaudoin L, Diana J, et al. (2008) Invariant
NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate
the central nervous system in a CD1d-independent manner. J Immunol 181:
2321–2329.
43. Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, et al. (2004) Presence
of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic
lateral sclerosis spinal cord tissue. Ann Neurol 55: 221–235.
44. Graves MC, Fiala M, Dinglasan LA, Liu NQ, Sayre J, et al. (2004) Inflammation
in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated
macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor
Neuron Disord 5: 213–219.
45. Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, et al. (2001) Protective
autoimmunity is a physiological response to CNS trauma. J Neurosci 21:
3740–3748.
46. Shaked I, Tchoresh D, Gersner R, Meiri G, Mordechai S, et al. (2005)
Protective autoimmunity: interferon-gamma enables microglia to remove
glutamate without evoking inflammatory mediators. J Neurochem 92:
997–1009.
47. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and
defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice.
J Neurosci 28: 8354–8360.
48. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, et al. (2000) T cell immunity to
copolymer 1 confers neuroprotection on the damaged optic nerve: possible
therapy for optic neuropathies. Proc Natl Acad Sci U S A 97: 7446–7451.
49. Bakalash S, Kessler A, Mizrahi T, Nussenblatt R, Schwartz M (2003) Antigenic
specificity of immunoprotective therapeutic vaccination for glaucoma. Invest
Ophthalmol Vis Sci 44: 3374–3381.
50. Frenkel D, Maron R, Burt DS, Weiner HL (2005) Nasal vaccination with a
proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a
mouse model of Alzheimer disease. J Clin Invest 115: 2423–2433.
51. Angelov DN, Waibel S, Guntinas-Lichius O, Lenzen M, Neiss WF, et al. (2003)
Therapeutic vaccine for acute and chronic motor neuron diseases: implications
for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 100: 4790–4795.
52. Habisch HJ, Schwalenstocker B, Danzeisen R, Neuhaus O, Hartung HP, et al.
(2007) Limited effects of glatiramer acetate in the high-copy number hSOD1-
G93A mouse model of ALS. Exp Neurol 206: 288–295.
NKT Cells and Liver Pathology in ALS
PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e2237453. Haenggeli C, Julien JP, Mosley RL, Perez N, Dhar A, et al. (2007) Therapeutic
immunization with a glatiramer acetate derivative does not alter survival in
G93A and G37R SOD1 mouse models of familial ALS. Neurobiol Dis 26:
146–152.
54. Schwartz M, Bukshpan S, Kunis G (2008) Application of glatiramer acetate to
neurodegenerative diseases beyond multiple sclerosis: the need for disease-
specific approaches. BioDrugs 22: 293–299.
55. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K (2007) Non-cell
autonomous effect of glia on motor neurons in an embryonic stem cell-based
ALS model. Nat Neurosci 10: 608–614.
56. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, et al. (1999) Liver-derived insulin-
like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not
required for postnatal body growth in mice. Proc Natl Acad Sci U S A 96:
7088–7092.
57. Desbois-Mouthon C, Wendum D, Cadoret A, Rey C, Leneuve P, et al. (2006)
Hepatocyte proliferation during liver regeneration is impaired in mice with liver-
specific IGF-1R knockout. FASEB J 20: 773–775.
58. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding
proteins: biological actions. Endocr Rev 16: 3–34.
59. Ricort JM (2004) Insulin-like growth factor binding protein (IGFBP) signalling.
Growth Horm IGF Res 14: 277–286.
60. Leu JI, Crissey MA, Taub R (2003) Massive hepatic apoptosis associated with
TGF-beta1 activation after Fas ligand treatment of IGF binding protein-1-
deficient mice. J Clin Invest 111: 129–139.
61. Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I (2005) Choroid
plexus megalin is involved in neuroprotection by serum insulin-like growth factor
I. J Neurosci 25: 10884–10893.
62. Masui Y, Mozai T, Kakehi K (1985) Functional and morphometric study of the
liver in motor neuron disease. J Neurol 232: 15–19.
63. Harraz MM, Marden JJ, Zhou W, Zhang Y, Williams A, et al. (2008) SOD1
mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a
familial ALS model. J Clin Invest 118: 659–670.
64. Yamada Y, Kirillova I, Peschon JJ, Fausto N (1997) Initiation of liver growth by
tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor
necrosis factor receptor. Proc Natl Acad Sci U S A 94: 1441–1446.
65. Ito H, Ando K, Nakayama T, Taniguchi M, Ezaki T, et al. (2003) Role of
Valpha 14 NKT cells in the development of impaired liver regeneration in vivo.
Hepatology 38: 1116–1124.
66. Dal Canto MC, Gurney ME (1994) Development of central nervous system
pathology in a murine transgenic model of human amyotrophic lateral sclerosis.
Am J Pathol 145: 1271–1279.
67. Kong J, Xu Z (1998) Massive mitochondrial degeneration in motor neurons
triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant
SOD1. J Neurosci 18: 3241–3250.
68. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, et al. (1995) An
adverse property of a familial ALS-linked SOD1 mutation causes motor neuron
disease characterized by vacuolar degeneration of mitochondria. Neuron 14:
1105–1116.
69. Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms
involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27:
723–749.
70. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, et al. (2008)
Type I NKT cells protect (and type II NKT cells suppress) the host’s innate
antitumor immune response to a B-cell lymphoma. Blood 111: 5637–5645.
71. Roelofs-Haarhuis K, Wu X, Gleichmann E (2004) Oral tolerance to nickel
requires CD4+ invariant NKT cells for the infectious spread of tolerance and the
induction of specific regulatory T cells. J Immunol 173: 1043–1050.
72. Santodomingo-Garzon T, Han J, Le T, Yang Y, Swain MG (2008) Natural killer
T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T
cells to the liver in mice. Hepatology.
73. Deng ZB, Liu Y, Liu C, Xiang X, Wang J, et al. (2009) Immature myeloid cells
induced by a high-fat diet contribute to liver inflammation. Hepatology 50:
1412–1420.
74. Butovsky O, Kunis G, Koronyo-Hamaoui M, Schwartz M (2007) Selective
ablation of bone marrow-derived dendritic cells increases amyloid plaques in a
mouse Alzheimer’s disease model. Eur J Neurosci 26: 413–416.
75. Kang J, Rivest S (2007) MyD88-deficient bone marrow cells accelerate onset
and reduce survival in a mouse model of amyotrophic lateral sclerosis. J Cell Biol
179: 1219–1230.
NKT Cells and Liver Pathology in ALS
PLoS ONE | www.plosone.org 12 August 2011 | Volume 6 | Issue 8 | e22374